Stockreport

ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

ProQR Therapeutics N.V. - Ordinary Shares  (PRQR) 
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: proqr.com
PDF Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment.A clinically meaningful [Read more]